Iterative Therapeutics, Inc.

Other

Barry G W Arnason

David M White

Mark A Jensen

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc&#x3b3;R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc&#x3b3;R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgGfused to the framework region of human IgG. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc&#x3b3;R in autoimmune disorders.

Nucleic acids related to fusion proteins

Method of using fusion proteins

The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and nucleic acids used to encode the inventive polypeptides.

Methods and compositions involving polymeric immunoglobulin fusion proteins

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc&#x3b3;R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc&#x3b3;R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgGfused to the framework region of human IgG. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc&#x3b3;R in autoimmune disorders.

Growing community of inventors

Chicago, IL, United States of America

Barry G W Arnason